Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
